CRISPR Therapeutics CRSP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$122.93M+9.6% | -$130.61M-250% | -$106.44M-23.9% | -$208.55M-65.0% | -$136M-16.6% | ||
| $4.32M-8.8% | $5.66M+16.9% | $4.43M-6.5% | $4.65M-4.0% | $4.74M-2.0% | ||
| $16.32M-19.2% | $18.08M-17.6% | $16.6M-22.9% | $17.61M-25.6% | $20.21M+4.2% | ||
| -$108.9M-102% | -$92.55M-85.0% | -$84.63M+20.8% | -$113.88M-19.1% | -$53.95M-149% | ||
| $504K+145% | $517K+104% | $74K-66.2% | $117K-83.5% | $206K-71.4% | ||
| -$410.74M-1,979% | —— | -$119.23M+26.2% | $69.98M+155% | -$19.76M+79.8% | ||
| $591.91M+5,490% | $116.41M+590% | $296.77M+2,978% | $2.26M— | $10.59M-96.5% | ||
| $72.24M+215% | $61.06M— | $92.88M+136% | -$41.57M— | -$63.07M-120% | ||
| -$109.4M-102% | -$93.07M-85.1% | -$84.71M+20.9% | -$114M-18.4% | -$54.15M-150% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CRISPR Therapeutics generate?
- CRISPR Therapeutics (CRSP) generated -$400.0M in operating cash flow over the trailing twelve months.
- What is CRISPR Therapeutics's free cash flow?
- After $1.2M of capital expenditures, CRISPR Therapeutics's free cash flow was -$401.2M over the trailing twelve months, down 30.3% year over year.
- Where does CRISPR Therapeutics's cash flow data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
